A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps
Key facts
- Who runs it
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 228 people enrolled
- Started
- 19 Sept 2024
- Ended
- 13 Aug 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- GR1802
- Placebo
- Record updated
- 29 October 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Diagnosed as CRSwNP and treated with systemic glucocorticoid within 2 years before screening; and/or those who had undergone surgery for nasal polyps before screening
- An endoscopic bilateral NPS at screening/lead-in period and the baseline period of at least 5 out of a maximum score of 8 (with a minimum socre of 2 in each nasal cavity)
- Nasal congestion/blockade/obstruction with moderate or severe symptom severity at at screening period (score 2 or 3 )
- Willing to sign an informed consent, able to comply with clinic visits and study-related procedures as per protocol
Who cannot take part
- Biologic therapy within 5 half-lives or within 10 weeks before baseline
- Anti-IL-4Rα antibody before screening
- An experimental drug within 5 half-lives or 1 months before baseline
- Initiation of allergen immunotherapy within 3 months before screening
- Participants receiving leukotriene antagonist/modifier before screening unless on continous treatment for at least 30 days
- Participants who have undergone any intranasal and/or sinus surgery within 6 months before screening
- Systemic immunosuppressant to treat inflammatory disease or autoimmune disease within 2 months or 5 half-lives before baseline
- Acute sinusitis or upper respiratory infection within a defined time period before screening
- A nasal cavity tumor (malignant or benign)
- Presence of another diagnosis associated with nasal polyps (i.e., eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, Young's syndrome, cystic fibrosis)
- Participants with FEV1 50% or less of predicted normal were excluded
- Evidence of fungal rhinosinusitis
- Rhinitis medicamentosa
- Nasal septal deviation occluding at least one nostril
- Antrochoanal polyps
- Pregnant or lactating woman
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if GR1802 works to treat severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. It will also learn about the safety of GR1802. The main questions it aims to answer are:
Read full original descriptionShow less
1. Does GR1802 reduce the need for surgery and systemic corticosteroid use? 2. What medical problems do participants have when taking GR1802?
Researchers will compare GR1802 to a placebo (a look-alike substance that contains no drug) to see if GR1802 works to treat CRSwNP.
Participants will:
Take GR1802 or a placebo once every 2 weeks for 13months. Visit the clinic once every 2 weeks for checkups and tests. Keep a diary of their symptoms and the dosage and number of times they use mometasone furoate nasal spray.
The 2 groups in the trial
- GR1802 groupTreatment being tested
GR1802 300mg is administrated every 2 weeks (first dose doubled) for a total of 26 doses, of which an additional 2 ml of placebo is given at week 24.
Treatment: GR1802
- placebo groupPlacebo, for comparison
Placebo is administered every 2 weeks for the first 16 weeks. GR1802 is given every 2 weeks from week 24 to W50.
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy, Safety, and Immunogenicity of GR1802 in Participants With Chronic Rhinosinusitis With Nasal Polyps
- Record updated
- 29 October 2026